| scholarly article | Q13442814 |
| P50 | author | Vivek Choudhary | Q79780736 |
| P2093 | author name string | Ying-Ying Tsai | |
| Xunsheng Chen | |||
| Wendy B Bollag | |||
| Ding Xie | |||
| Lawrence Olala | |||
| Mutsa Seremwe | |||
| Zhi-qiang Pan | |||
| P2860 | cites work | Reduced expression of 11β-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARγ but increased PPARα expression | Q45221094 |
| A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. | Q53286031 | ||
| Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids | Q59282232 | ||
| The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders | Q24613957 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review | Q26866784 | ||
| Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha | Q27637763 | ||
| Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 | ||
| Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis | Q28246252 | ||
| Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress | Q29615495 | ||
| An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) | Q29615693 | ||
| Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. | Q30483132 | ||
| Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention | Q33878917 | ||
| Human adrenocortical carcinoma cell lines | Q34216956 | ||
| Thiazolidinediones | Q34346862 | ||
| Comparison of aldosterone production among human adrenocortical cell lines | Q34723557 | ||
| Control of aldosterone secretion: a model for convergence in cellular signaling pathways | Q35715226 | ||
| PPARgamma in human and mouse physiology | Q36063081 | ||
| The many faces of PPARgamma | Q36344625 | ||
| Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. | Q36509300 | ||
| Effects of pioglitazone on lipid and lipoprotein metabolism | Q36909527 | ||
| Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line | Q36971988 | ||
| Estrogens and glucocorticoid hormones in adipose tissue metabolism | Q37017889 | ||
| The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. | Q37079828 | ||
| PERK and PKR: old kinases learn new tricks | Q37140418 | ||
| The effects of ACTH on steroid metabolomic profiles in human adrenal cells | Q37174282 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes | Q38160494 | ||
| Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production | Q39627792 | ||
| Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes | Q40219535 | ||
| Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone | Q40839780 | ||
| Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages. | Q42321362 | ||
| Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals | Q43087875 | ||
| Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. | Q43089536 | ||
| The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. | Q43257116 | ||
| Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma | Q43993728 | ||
| Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. | Q44001857 | ||
| Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, acinar cell damage, and systemic inflammation in acute pancreatitis | Q44154350 | ||
| Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease | Q44311462 | ||
| Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy | Q44433534 | ||
| Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. | Q44786947 | ||
| P433 | issue | 1-2 | |
| P921 | main subject | cortisol | Q190875 |
| adrenocortical carcinoma | Q918285 | ||
| P304 | page(s) | 119-128 | |
| P577 | publication date | 2014-07-17 | |
| P1433 | published in | Molecular and Cellular Endocrinology | Q1573600 |
| P1476 | title | The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells | |
| P478 | volume | 394 |
| Q47129762 | Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells |
| Q55088439 | Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches. |
| Q58556376 | Higher Screening Aldosterone to Renin Ratio in Primary Aldosteronism Patients with Diabetes Mellitus |
| Q89361055 | M3-subtype muscarinic receptor activation stimulates intracellular calcium oscillations and aldosterone production in human adrenocortical HAC15 cells |
| Q28389245 | Mechanisms mediating environmental chemical-induced endocrine disruption in the adrenal gland |
| Q91883945 | Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway |
| Q92471912 | Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration |
| Q41362011 | Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure |
| Q47340492 | Targeted disruption of the KCNJ5 gene in the female mouse lowers aldosterone levels. |
Search more.